Showing 2371-2380 of 8791 results for "".
Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execPsoriasis Comorbidities: Assessing Risks and the Role of Dermatologists
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities-assessing-risks-and-the-role-of-dermatologists-/18242/Ronald Prussick, MD discusses the most common comorbidities of psoriasis and the risks patients have for cardiovascular issues, depression, fatty liver disease, vitamin D deficiency, and more. He talks to host Nancy Samolitis, MD about the role dermatologists play in assessing and treating these risValeant's Plan for Derm; VCS Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-valeant-s-plan-for-derm-vcs-highlights/18587/Amid reports that its Obagi and Solta units may be sold off, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Vegas Cosmetic Surgery has wrapped up its 12th program, gathering dermatologists, plastic surgeons, facial pBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Journal Club: Combination Therapy With Dupilumab and Upadacitinib
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combination-therapy-with-dupilumab-and-upadacitinib/32408/Neal Bhatia, MD, FAAD, and Ted Lain, MD, MBA, FAAD, discuss the International Journal of Dermatology article “Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis,” and their own experiences with similar treatment strategies.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.Strategies for Success: Tips on Running a Successful Dermatology Practice
https://practicaldermatology.com/conferences/scale-2023/strategies-for-success-tips-on-running-a-successful-dermatology-practice/20199/Mark D. Kaufmann, MD, Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery Clinics, discusses what it takes to run a successful dermatology practice today, including the importance of leveraging data to prove value and sharpening business skills.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.